Clinical trial · Observational
Phase I Prognostic Online (PIPO) Tool
Phase I Prognostic Online (PIPO) Tool: a New Aid to Improve Patient Selection for Early Phase Clinical Trials
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Clinical trials are studies that test new treatments to see if they work and are safe for people with certain illnesses. Phase I clinical trials are the earliest stage of testing, where researchers give a new treatment to a small group of people to see if it's safe and how much of it can be given before causing harmful side effects. Selecting patients for these trials is challenging, especially since most of them have already tried other treatments that didn't work. To make sure patients are not harmed during the trial, researchers need to estimate how long they might live, so they don't give the new treatment to someone who might not live long enough to see if it works. Doctors use a variety of tools to estimate how long a patient might live, but it's not always easy to do. To help with this, researchers have developed a new tool called the Phase I prognostic online (PIPO) tool. It helps estimate how long a patient might live by looking at different factors like age, the type of cancer, and other medical conditions. This tool can help doctors decide if a patient should be included in a clinical trial or not. The researchers plan to test this tool to see how well it works, with the goal of using it in clinical practice to help doctors estimate life expectancy and select patients for clinical trials. This will make it easier for doctors to help their patients get access to new treatments that might help them.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oncology | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immune checkpoint inhibitor, targeted agents | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients candidates for Phase 1 trials
- interventionNames
- Drug: Immune checkpoint inhibitor, targeted agents
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 1 year
- description
- overall survival as a continuous variable and 3 months overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: \- Participants must have been enrolled in a VHIO phase 1 clinical trial or phase 2 basket trial included in this study.
References
Publications (0)
Data not yet available